HRTX News & Events

Reports Q4 revenue $40.588M, consensus $39.53M. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of Heron's Acute Care franchise, underscoring the success of the strategic decisions we implemented to unlock the full potential of these assets," said Craig Collard, Chief Executive Officer of Heron. "The milestones achieved in 2025, particularly for ZYNRELEF - including enhanced distributor-partner incentives, the seamless completion of the Vial Access Needle transition, and CMS approval of a product-specific J-Code - are already accelerating adoption and strengthening our competitive position in a large and underpenetrated market."

Sees FY26 adjusted EBITDA $10M to $20M

"We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF and APONVIE," said Craig Collard, CEO. "In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year." Preliminary Q4 and FY25 Updates: Net revenue of approximately $40.5M for the three months ended December 31. ZYNRELEF net revenue of approximately $12.5M for the three months ended December 31. APONVIE net revenue of approximately $3.8M for the three months ended December 31. CINVANTI net revenue of approximately $22.9M for the three months ended December 31. SUSTOL net revenue of approximately $1.3M for the three months ended December 31. Net revenue of approximately $154.9M for FY25. ZYNRELEF delivered the largest quarter-over-quarter revenue increase within the portfolio in Q4.